Phase II Study of Weekly Paclitaxel for Relapsed and Refractory Small Cell Lung Cancer
2006
The purpose of this study was to evaluate the efficacy and toxicity of single-agent paclitaxel given weekly to patients with relapsed and refractory small cell lung cancer (SCLC). Patients were treated with 80 mg/m 2 paclitaxel administered weekly for 1 h for 6 weeks in an 8-week cycle. Twenty-two patients were enrolled, 21 of whom were eligible. The patient characteristics included: 20 males, 1 female; median age 66 years (range 48 - 75); performance status 0/1 in 19 and 2 in 5 patients. Grade 3/4 leukopenia and neutropenia occurred in 47.5% and 64%, respectively. Other grade 3/4 toxicities included infection, skin rash, neuropathy and pulmonary toxicity. There were 5 partial responses in 3 out of the 11 sensitive cases and 2 out of the 10 refractory cases, respectively. Paclitaxel, administered as a weekly infusion at a dose of 80 mg/m 2 , was effective in treating relapsed and refractory SCLC. More than 95% of patients with small cell lung cancer (SCLC), who are initially treated with paclitaxel 80 mg/m 2 , present a relapse and their response to a second-line therapy is poor. The responses obtained are usually brief, and the median survival is generally less than 4 months (1). Nevertheless, second-line chemotherapy may provide a significant palliation of symptoms and does result in a prolongation of survival in many patients. The activity of paclitaxel as a single agent has been
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
16
References
51
Citations
NaN
KQI